(ABT) Abbott Laboratories - NYSE
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 158.122m USD | Total Return: -32.2% in 12m
Avg Turnover: 963M
EPS Trend: 64.0%
Qual. Beats: 0
Rev. Trend: 97.2%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Abbott Laboratories is a diversified global healthcare company operating across four primary segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its portfolio includes generic pharmaceuticals, laboratory diagnostic systems, pediatric and adult nutritionals, and advanced medical hardware for cardiovascular and neuromodulation treatments.
The company utilizes a vertically integrated business model to manage the manufacturing and distribution of high-volume consumables, such as infant formula and glucose monitoring strips, alongside specialized clinical instruments. As a constituent of the Health Care Equipment sub-industry, Abbott operates in a sector characterized by high research and development requirements and rigorous regulatory oversight by the FDA and international equivalents.
For a detailed analysis of the companys long-term valuation metrics, you may wish to consult ValueRay. Abbott Laboratories, originally founded as the Abbott Alkaloidal Company, transitioned to its current name in 1915 and maintains a significant presence in both emerging and developed markets.
- FreeStyle Libre market share expansion drives long-term medical device revenue growth
- Pediatric nutrition recovery stabilizes margins following manufacturing and supply chain disruptions
- Diagnostic segment revenue normalizes as COVID-19 testing demand continues to decline
- New product approvals in structural heart and electrophysiology boost high-margin sales
- Emerging market expansion accelerates volume growth for established pharmaceutical product segment
| Net Income: 6.28b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.49 > 1.0 |
| NWC/Revenue: 15.80% < 20% (prev 23.97%; Δ -8.17% < -1%) |
| CFO/TA 0.09 > 3% & CFO 9.46b > Net Income 6.28b |
| Net Debt (27.7b) to EBITDA (11.4b): 2.44 < 3 |
| Current Ratio: 1.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.75b) vs 12m ago -0.01% < -2% |
| Gross Margin: 56.38% > 18% (prev 51.42%; Δ 4.96% > 0.5%) |
| Asset Turnover: 47.04% > 50% (prev 51.99%; Δ -4.94% > 0%) |
| Interest Coverage Ratio: 29.83 > 6 (EBIT TTM 8.20b / Interest Expense TTM 275.0m) |
| A: 0.06 (Total Current Assets 25.5b - Total Current Liabilities 18.4b) / Total Assets 110b |
| B: 0.45 (Retained Earnings 50.0b / Total Assets 110b) |
| C: 0.09 (EBIT TTM 8.20b / Avg Total Assets 95.9b) |
| D: 0.90 (Book Value of Equity 52.1b / Total Liabilities 57.7b) |
| Altman-Z'' = 3.42 = A |
| DSRI: 1.05 (Receivables 8.21b/7.33b, Revenue 45.1b/42.3b) |
| GMI: 0.91 (GM 51.42% / 56.38%) |
| AQI: 1.13 (AQ_t 0.66 / AQ_t-1 0.58) |
| SGI: 1.07 (Revenue 45.1b / 42.3b) |
| TATA: -0.03 (NI 6.28b - CFO 9.46b) / TA 110b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of June 11, 2026, the stock is trading at USD 89.17 with a total of 11,850,531 shares traded.
Over the past week, the price has changed by +2.51%,
over one month by +8.01%,
over three months by -18.83% and
over the past year by -32.16%.
Abbott Laboratories has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy ABT.
- StrongBuy: 12
- Buy: 7
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 117.3 | 31.5% |
P/E Trailing = 25.4286
P/E Forward = 15.873
P/S = 3.3571
P/B = 2.9098
P/EG = 1.2915
Revenue TTM = 45.1b USD
EBIT TTM = 8.20b USD
EBITDA TTM = 11.4b USD
Long Term Debt = 29.6b USD (from longTermDebt, last quarter)
Short Term Debt = 4.41b USD (from shortTermDebt, last quarter)
Debt = 35.0b USD (from shortLongTermDebtTotal, last quarter) + Leases 931.0m
Net Debt = 27.7b USD (calculated: Debt 35.0b - CCE 7.29b)
Enterprise Value = 186b USD (158b + Debt 35.0b - CCE 7.29b)
Interest Coverage Ratio = 29.83 (Ebit TTM 8.20b / Interest Expense TTM 275.0m)
EV/FCF = 25.18x (Enterprise Value 186b / FCF TTM 7.38b)
FCF Yield = 3.97% (FCF TTM 7.38b / Enterprise Value 186b)
FCF Margin = 16.35% (FCF TTM 7.38b / Revenue TTM 45.1b)
Net Margin = 13.91% (Net Income TTM 6.28b / Revenue TTM 45.1b)
Gross Margin = 56.38% ((Revenue TTM 45.1b - Cost of Revenue TTM 19.7b) / Revenue TTM)
Gross Margin QoQ = 56.28% (prev 57.05%)
Tobins Q-Ratio = 1.68 (Enterprise Value 186b / Total Assets 110b)
Interest Expense / Debt = 0.79% (Interest Expense 275.0m / Debt 35.0b)
Taxrate = 22.87% (1.86b / 8.14b)
NOPAT = 6.33b (EBIT 8.20b * (1 - 22.87%))
Current Ratio = 1.39 (Total Current Assets 25.5b / Total Current Liabilities 18.4b)
Debt / Equity = 0.67 (Debt 35.0b / totalStockholderEquity, last quarter 52.1b)
Debt / EBITDA = 2.44 (Net Debt 27.7b / EBITDA 11.4b)
Debt / FCF = 3.75 (Net Debt 27.7b / FCF TTM 7.38b)
Total Stockholder Equity = 51.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.54% (Net Income 6.28b / Total Assets 110b)
RoE = 12.20% (Net Income TTM 6.28b / Total Stockholder Equity 51.4b)
RoCE = 10.12% (EBIT 8.20b / Capital Employed (Equity 51.4b + L.T.Debt 29.6b))
RoIC = 6.72% (NOPAT 6.33b / Invested Capital 94.2b)
WACC = 4.41% (E(158b)/V(193b) * Re(5.25%) + D(35.0b)/V(193b) * Rd(0.79%) * (1-Tc(0.23)))
Discount Rate = 5.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -27.60 | Cagr: -0.03%
[DCF] Terminal Value 76.75% ; FCFF base≈7.09b ; Y1≈7.76b ; Y5≈9.75b
[DCF] Fair Price = 69.69 (EV 149b - Net Debt 27.7b = Equity 121b / Shares 1.74b; r=8.35% [WACC [floored]]; 5y FCF grow 10.83% → 2.50% )
EPS Correlation: 64.00 | EPS CAGR: 2.97% | SUE: 0.0 | # QB: 0
Revenue Correlation: 97.21 | Revenue CAGR: 4.71% | SUE: 1.13 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.28 | Chg30d=-0.07% | Revisions=-33% | Analysts=22
EPS next Quarter (2026-09-30): EPS=1.42 | Chg30d=-0.05% | Revisions=+0% | Analysts=22
EPS current Year (2026-12-31): EPS=5.48 | Chg30d=-0.01% | Revisions=-14% | GrowthEPS=+6.5% | GrowthRev=+13.5%
EPS next Year (2027-12-31): EPS=6.06 | Chg30d=-0.05% | Revisions=-33% | GrowthEPS=+10.5% | GrowthRev=+9.0%
[Analyst] Revisions Ratio: -33%